Phaseline

Companies › Guangzhou FineImmune Biotechnology

Guangzhou FineImmune Biotechnology: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FIT003 TAL-T (Tumor Associated Lymph node T cell)
Autologous tumor-associated lymph node T cells, expanded ex vivo
–Phase 1Advanced Solid Tumor; Tumor Associated Lymph Node T CellDec 2026
Super1 TCR-T
T-cell receptor engineered T cell targeting NY-ESO-1
NY-ESO-1Phase 1SarcomaApr 2027
Super CAR-T
GPC3-targeted CAR-T cell therapy
GPRC3Phase 1Advanced Hepatocellular Carcinoma (HCC)Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06302062FIT003 TAL-T (Tumor Associated Lymph node T cell)Phase 1Advanced Solid TumorOncologyDec 2025
NCT06716619FIT003 TAL-T (Tumor Associated Lymph node T cell)Phase 1Tumor Associated Lymph Node T CellOncologyDec 2026
NCT06942143Super1 TCR-TPhase 1SarcomaOncologyApr 2027
NCT07493044Super CAR-TPhase 1Advanced Hepatocellular Carcinoma (HCC)OncologyApr 2028

Targets

GPRC3 (1) NY-ESO-1 (1)

Companies with the same targets

AstraZeneca OriCell Therapeutics Takara Bio TCRCure Biopharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.